Loading...
XNAS
OMCL
Market cap1.58bUSD
Oct 08, Last price  
34.83USD
1D
-1.08%
1Q
-22.46%
Jan 2017
2.74%
IPO
297.60%
Name

Omnicell Inc

Chart & performance

D1W1MN
XNAS:OMCL chart
P/E
771.94
P/S
1.34
EPS
0.05
Div yield, %
—
Shrs. gr., 5y
1.17%
Rev. gr., 5y
5.84%
Revenues
1.18b
+6.53%
154,710,000213,081,000251,865,000213,457,000222,407,000245,535,000314,027,000380,585,000440,900,000484,559,000692,623,000716,165,000787,309,000897,027,000892,208,0001,132,018,0001,295,947,0001,147,112,0001,112,238,0001,184,845,000
Net income
2m
-83.62%
10,365,00043,295,00012,724,000444,0004,892,00010,389,00016,161,00023,979,00030,518,00030,760,000603,00020,605,00037,729,00061,338,00032,194,00077,849,0005,648,000-20,371,00012,531,0002,052,000
CFO
127m
-32.19%
19,507,00037,227,00019,535,00043,130,00020,599,00031,243,00039,484,00055,263,00065,163,00033,762,00047,937,00024,834,000103,966,000145,008,000185,870,000231,809,00077,781,000181,094,000187,722,000127,300,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Related entities

Subsidiaries (9)
AESYNT INCORPORATED
AESYNT S.R.L.
OMNICELL
OMNICELL B.V.
OMNICELL GMBH
OMNICELL INDIA PRIVATE LIMITED
OMNICELL LIMITED
OMNICELL SRL
AESYNT CANADA INC.

Key people

Randall A. Lipps
Chairman of the Board, President, Chief Executive Officer · since 2002
Chief Financial Officer, Executive Vice President · since 2015
Nhat H. Ngo
Executive Vice President - Marketing, Strategy and Business Development · since 2018
Scott P. Seidelmann
Executive Vice President and Chief Commercial Officer · since 2018
Joseph B. Spears
Senior Vice President, Chief Accounting Officer, Corporate Controller · since 2019
Robin Gene Seim
Director · since 2019
Joanne B. Bauer
Independent Director · since 2014
Vance B. Moore
Independent Director · since 2012
Independent Director · since 2013
Gary S. Petersmeyer
Independent Director · since 2007
Bruce E. Scott
Independent Director · since 2019
Bruce D. Smith
Independent Director · since 2014
Sara J. White
Independent Director · since 2003
IPO date
Aug 08, 2001
Employees
3,780
Domiciled in
US
Incorporated in
US
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
4220 NORTH FREEWAY
FORT WORTH, TX 76137
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT